UBS initiates Amgen, Inc.(NASDAQ:AMGN ) with a Neutral and price target of $185. During the next four years Amgen sales growth will face intensifying headwinds to Enbrel and key legacy products. The late-stage pipeline,

UBS initiates Celgene Corporation(NASDAQ:CELG) with a Buy and price target of $140. Robust top-line growth has become a rarity in large-cap biotech, and against that backdrop, Celgene has and should continue to stand out